Light chain (AL) Amyloidosis/Primary

Cardiac amyloidosis is a restrictive cardiomyopathy that results from the deposition of misfolded light chain or transthyretin proteins, most commonly, in cardiac…

Marina Ramirez-Alvarado is a Professor of Biochemistry and Molecular Biology at the Mayo Clinicexternal link, opens in a new tab, Rochester, Minnesota. She studies…

Assoc Prof @BUMedicine. @The_BMC hematologist. Tweeting about all things hematology and AL #Amyloidosis in particular. The J is for Jenius.

Vaishali Sanchorawala is the Director of the Autologous Stem Cell Transplantation Program at Boston Medical Center and has been affiliated with the Amyloidosis…

Heather J. Landau is a board-certified oncologist and hematologist, and works as part of a multidisciplinary team caring for patients with hematologic disorders.…

Eli Muchtar is a hematologist at Mayo clinic, Rochester, Minnesota. He received his medical degree from Ben Gurion University of the Negev followed by residency in…

A new staging system developed with a more accessible test to predict the chance of survival in patients living with light chain (AL) amyloidosis. Led by…

Scientists at Scripps Research have identified a group of small molecules that prevent structural changes to proteins that are at the root of AL amyloidosis, a…

Prothena Corporation PLC, a clinical-stage neuroscience company, today reported final results from the Phase 3 VITAL Amyloidosis study of NEOD001 (birtamimab) in…

Updated research regarding the ANDROMEDA study presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, indicated the…